Dodel R - Search Results

1

Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.

Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, Glynn RJ, Balzer-Geldsetzer M, Dodel R, Tackenberg B. Mengel D, et al. Among authors: dodel r. Muscle Nerve. 2018 Nov;58(5):681-687. doi: 10.1002/mus.26315. Epub 2018 Oct 3. Muscle Nerve. 2018. PMID: 30073683

2

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Dodel R, et al. Ann Neurol. 2002 Aug;52(2):253-6. doi: 10.1002/ana.10253. Ann Neurol. 2002. PMID: 12210803

3

Cost of illness and its predictors for Parkinson's disease in Germany.

Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Spottke AE, et al. Among authors: dodel r. Pharmacoeconomics. 2005;23(8):817-36. doi: 10.2165/00019053-200523080-00007. Pharmacoeconomics. 2005. PMID: 16097843

4

Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.

Hamer HM, Spottke A, Aletsee C, Knake S, Reis J, Strzelczyk A, Oertel WH, Rosenow F, Dodel R. Hamer HM, et al. Among authors: dodel r. Epilepsia. 2006 Dec;47(12):2165-72. doi: 10.1111/j.1528-1167.2006.00889.x. Epilepsia. 2006. PMID: 17201718 Free article.

5

Assessing health-related quality of life in patients with restless legs syndrome.

Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsche J, Giani G, Geraedts M, Trenkwalder C, Dodel R. Happe S, et al. Among authors: dodel r. Sleep Med. 2009 Mar;10(3):295-305. doi: 10.1016/j.sleep.2008.01.002. Epub 2008 Mar 24. Sleep Med. 2009. PMID: 18359664

6

Cost of epilepsy: a systematic review.

Strzelczyk A, Reese JP, Dodel R, Hamer HM. Strzelczyk A, et al. Among authors: dodel r. Pharmacoeconomics. 2008;26(6):463-76. doi: 10.2165/00019053-200826060-00002. Pharmacoeconomics. 2008. PMID: 18489198 Review.

7

Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Eggert KM, Reese JP, Oertel WH, Dodel R. Eggert KM, et al. Among authors: dodel r. CNS Drugs. 2008;22(10):841-60. doi: 10.2165/00023210-200822100-00005. CNS Drugs. 2008. PMID: 18788836 Review.

8

[Direct costs for Parkinson's treatment in private neurology practices in Berlin].

Ehret R, Balzer-Geldsetzer M, Reese JP, Dodel I, Becker E, Christopher A, Friedrich H, Kraemer S, Lüer W, Müngersdorf M, Puzich R, Rohr A, Schultes-Platzek I, Siefjediers V, Tiel-Wilck K, Oertel WH, Dodel R. Ehret R, et al. Among authors: dodel i, dodel r. Nervenarzt. 2009 Apr;80(4):452-8. doi: 10.1007/s00115-009-2671-y. Nervenarzt. 2009. PMID: 19252890 German.

9

The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors.

Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. Bach JP, et al. Among authors: dodel r. Cancer. 2009 May 15;115(10):2031-40. doi: 10.1002/cncr.24245. Cancer. 2009. PMID: 19326434 Free article. Review.

10

Costs of illness in a Russian cohort of patients with Parkinson's disease.

Winter Y, von Campenhausen S, Popov G, Reese JP, Klotsche J, Bötzel K, Gusev E, Oertel WH, Dodel R, Guekht A. Winter Y, et al. Among authors: dodel r. Pharmacoeconomics. 2009;27(7):571-84. doi: 10.2165/11310160-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663528

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

342 results

Search Page